Hyung-Bae Park

Title: Innovations of Hyung-Bae Park in Cancer Therapy

Introduction

Hyung-Bae Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer therapy through his innovative patents. With a total of two patents, his work focuses on enhancing the efficacy of chimeric antigen receptor (CAR) T cell therapies.

Latest Patents

One of his latest patents is titled "Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell." This invention relates to a novel chimeric antigen receptor that includes a CD99 region, which plays a crucial role in stabilizing immune synapses. The CD99-based CAR-T cells are capable of forming stable immune synapses with tumor cells, leading to improved therapeutic efficiency in cancer treatment.

Another significant patent is "Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof." This invention involves chimeric antibody receptors linked with anti-cotinine antibodies. The T cells presenting this receptor can secrete interferon gamma specifically for target molecules, inducing cell death in cells expressing those molecules. Additionally, a cytotoxic agent conjugated with cotinine can be administered to eliminate the chimeric antigen receptor T cells, thereby managing immune side effects.

Career Highlights

Hyung-Bae Park has worked with prominent organizations such as Ticaros Co., Ltd. and Seoul National University. His experience in these institutions has contributed to his expertise in the development of innovative cancer therapies.

Collaborations

He has collaborated with notable colleagues, including Kyungho Choi and Eun-Young Choi, further enhancing the impact of his research and inventions.

Conclusion

Hyung-Bae Park's innovative work in the field of cancer therapy through his patents demonstrates his commitment to advancing medical science. His contributions have the potential to significantly improve treatment outcomes for cancer patients.